Fmr LLC Sells 323,427 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

FMR LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 70.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 134,292 shares of the medical research company's stock after selling 323,427 shares during the period. FMR LLC owned 0.26% of Charles River Laboratories International worth $26,452,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Truvestments Capital LLC grew its position in Charles River Laboratories International by 17.0% in the 3rd quarter. Truvestments Capital LLC now owns 2,407 shares of the medical research company's stock valued at $474,000 after buying an additional 350 shares in the last quarter. Fisher Asset Management LLC grew its position in Charles River Laboratories International by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 184,692 shares of the medical research company's stock valued at $36,379,000 after buying an additional 1,586 shares in the last quarter. Daiwa Securities Group Inc. grew its position in Charles River Laboratories International by 12.6% in the 3rd quarter. Daiwa Securities Group Inc. now owns 6,355 shares of the medical research company's stock valued at $1,252,000 after buying an additional 710 shares in the last quarter. Cerity Partners LLC grew its position in Charles River Laboratories International by 65.9% in the 3rd quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company's stock valued at $963,000 after buying an additional 1,943 shares in the last quarter. Finally, Citigroup Inc. grew its position in Charles River Laboratories International by 10.7% in the 3rd quarter. Citigroup Inc. now owns 236,141 shares of the medical research company's stock valued at $46,513,000 after buying an additional 22,788 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research report on Friday, September 20th. Citigroup lowered shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Bank of America lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Finally, TD Cowen raised their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Trading Down 2.3 %

Shares of CRL traded down $4.70 during midday trading on Tuesday, hitting $197.05. The stock had a trading volume of 414,395 shares, compared to its average volume of 618,158. The business has a 50-day simple moving average of $194.19 and a two-hundred day simple moving average of $203.56. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm has a market cap of $10.08 billion, a P/E ratio of 25.25, a price-to-earnings-growth ratio of 4.95 and a beta of 1.38. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm's revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.72 earnings per share. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).